drugset

drugset / Trial / NCT01112397

Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours

NCT01112397 ↗

Phase 1 Terminated 72 enrolled AstraZeneca

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is being conducted to assess the safety, tolerability and PK of AZD1480 in patients with advanced solid malignancies.

Timeline

Start: 2010-04
Primary completion: 2012-09
Completion: 2012-09

Outcome

Outcome not reported

Stopped: “Decision to stop development of AZD1480”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AZD1480	Small molecule	—	Oral

Indications